Adjuvant use of interferon α2b is not justified in patients with stage IIb/III melanoma

被引：0
|
作者：
Emilio Bajetta
机构：
[1] E Bajetta is Chief of Medical Oncology,
[2] IRCCS Fondazione 'Istituto Nazionale dei Tumori',undefined
[3] Milan,undefined
[4] Italy.,undefined
来源：
Nature Clinical Practice Oncology | 2008年 / 5卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The incidence of the skin malignancy, melanoma, is increasing and it often becomes refractory to common therapies after metastasis. In this Viewpoint the author discusses different therapeutic approaches for metastatic melanoma.
引用
收藏
页码：4 / 5
页数：1
相关论文
共 50 条
  • [31] Adjuvant therapy with pegylated interferon α-2b versus observation in resected stage III melanoma:: final results of EORTC 18991, a randomised phase 3 trial
    Eggermont, A. M. M.
    Suciu, S.
    Santinami, M.
    Testori, A.
    Kruit, W.
    Marsden, J.
    Punt, C. J. A.
    Sales, F.
    Gore, M.
    Mckie, R.
    Kusic, V.
    Dummer, R.
    Musat, E.
    Spatz, A.
    Keilholz, U.
    [J]. PIGMENT CELL & MELANOMA RESEARCH, 2008, 21 (02) : 290 - 290
  • [32] Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
    Daud, A. I.
    Xu, C.
    Hwu, W. -J.
    Urbas, P.
    Andrews, S.
    Papadopoulos, N. E.
    Floren, L. C.
    Yver, A.
    DeConti, R. C.
    Sondak, V. K.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (03) : 657 - 666
  • [33] Helping melanoma patients decide whether to choose adjuvant high-dose interferon-α2b
    Hurley, KE
    Chapman, PB
    [J]. ONCOLOGIST, 2005, 10 (09): : 739 - 742
  • [34] Intensified high-dose intravenous interferon alpha 2b (IFNa2b) for adjuvant treatment of stage III melanoma: A randomized phase III Italian Melanoma Intergroup (IMI) trial [ISRCTN75125874]
    Chiarion-Sileni, V.
    Guida, M.
    Romanini, A.
    Ridolfi, R.
    Mandala, M.
    Del Bianco, P.
    Silvestri, B.
    Medici, M.
    Michiara, M.
    Dalla Palma, M.
    Puccetti, O.
    Pigozzo, J.
    Laveder, F.
    De Salvo, G. L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [35] Intermediate dose interferon alfa 2 B (IFN alfa 2B) in adjuvant tratment for malignant melanoma
    Savio, Giuseppina
    Calabria, Caterina
    Laudani, Agata
    Pepe, Alessio
    Palmisano, Valentina
    Leonardi, Vita
    Usset, Antonella
    Arcuri, Carmen
    Giresi, Armando
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 168 - 168
  • [36] Inhibition of choroidal melanoma by interferon alpha 2b (IFNα2b)
    Neale, M
    Myatt, N
    Hungerford, JL
    Plowman, PN
    Cree, IA
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [37] Low-dose adjuvant interferon for stage III malignant melanoma
    Inman, JL
    Russell, GB
    Savage, P
    Levine, EA
    [J]. AMERICAN SURGEON, 2003, 69 (02) : 127 - 130
  • [38] Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
    Chevolet, Ines
    Schreuer, Max
    Speeckaert, Reinhart
    Neyns, Bart
    Hoorens, Isabelle
    van Geel, Nanja
    Kruese, Vibeke
    Hennart, Benjamin
    Allorge, Delphine
    Van Gele, Mireille
    Brochez, Lieve
    [J]. MELANOMA RESEARCH, 2015, 25 (04) : 357 - 361
  • [39] Toxicity of adjuvant treatment with high-dose interferon alpha 2b (HD-IFN) in high-risk stage III melanoma patients (pts): The Italian experience.
    Romanini, A
    Sarti, S
    Murr, R
    Doria, S
    Rondini, M
    Orlandini, C
    Menichetti, T
    Pigozzo, J
    Chiarion-Sileni, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 727S - 727S
  • [40] Response to "Helping melanoma patients decide whether to choose adjuvant high-dose interferon-α2b"
    Tarhini, Ahmad A.
    Shipe-Spotloe, Janice
    DeMark, Melissa
    Agarwala, Sanjiv S.
    Kirkwood, John M.
    [J]. ONCOLOGIST, 2006, 11 (05): : 538 - 539
12345